Classifier training Mann Whitney Predictor discovery in training set 4 Training set SJIA (12 F, 12 Q) POLY (13 F, 10 Q) 1 DIGE raw gel images SJIA (10.

Slides:



Advertisements
Similar presentations
Urine Proteomics in Kawasaki Disease Pawan Sharma 15 th October 2013.
Advertisements

Supplementary Figure 1 pH MW/1000 numberspot label Protein biomarker 11 (a,b)APO1 22GSN 33TTR 44FGB 55FGG 66APOD 77APOE 88 (a,b)ATIII 99 (a,b)A2M 1010.
SJIA flare signature analysis 2 Discovery set (ND.SAF vs. AF.QOM.RD.KD.FI) 1 LCMS raw spectra Peak finding peak alignment feature extraction Urine peptide.
Assuming normally distributed data! Naïve Bayes Classifier.
Samples vs. Distributions Distributions: Discrete Random Variable Distributions: Continuous Random Variable Another Situation: Sample of Data.
ML ALGORITHMS. Algorithm Types Classification (supervised) Given -> A set of classified examples “instances” Produce -> A way of classifying new examples.
Feature Selection Which features work best? One way to rank features: –Make a contingency table for each F –Compute abs ( log ( ad / bc ) ) –Rank the log.
Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.
Supplementary Figure 1 pH MW/1000 numberspot label Protein biomarker 11 (a,b)APO1 22GSN 33TTR 44FGB 55FGG 66APOD 77APOE 88 (a,b)ATIII 99 (a,b)A2M 1010.
Classifier training FDR analysis Predictor discovery in training set 4 Training set SJIA (12 F, 12 Q) 1 DIGE raw gel images Matched samples SJIA (10 F,
Evaluating Classifiers
Gene expression profiling identifies molecular subtypes of gliomas
Preliminary Studies on Proteomics and Peritoneal Dialysis Reference: Brewis IA, Topley N. Proteomics and peritoneal dialysis: Early days but clear potential.
BIOMARKER STUDIES IN CLINICAL TRIALS Vicki Seyfert-Margolis, PhD.
2007 GeneSpring MS GeneSpring for Metabolite BioMarker Analysis using Mass Spectrometry data Agilent Q-TOF VIP Visit Jan 16-17, 2007 Santa Clara, CA Thon.
High throughput urine biomarker discovery and integrative analysis for translational medicine High throughput urine biomarker discovery and integrative.
Exagen Diagnostics, Inc., all rights reserved Biomarker Discovery in Genomic Data with Partial Clinical Annotation Cole Harris, Noushin Ghaffari.
Sample peptides: -Class 1:1,2,3… -Class 2:1,2,3… -Class 3:1,2,3… SCX/RP-HPLC Collect 100 fractions on MALDI plates MALDI-TOF MS for each sample LC fraction.
Pfetin, as a Prognostic Biomarker of Gastrointestinal Stromal Tumors Revealed by Proteomics Yoshiyuki Suehara 1 3 4, Kunihiko Seki 2, Kiyonaga Fujii 1,
Transfer Learning Task. Problem Identification Dataset : A Year: 2000 Features: 48 Training Model ‘M’ Testing 98.6% Training Model ‘M’ Testing 97% Dataset.
Differential Protein Expression Analysis for Biomarker Discovery.
Fresh look on sepsis biomarkers: the ICU consultant's perspective Dr Tamas Szakmany 8 th July, 2015.
Marc Bonin Department of Rheumatology and Clinical Immunology Charité University Hospital Charitéplatz 1 D Berlin Germany Tel: +49(0)
A Short Overview of Microarrays Tex Thompson Spring 2005.
Class Prediction and Discovery Using Gene Expression Data Donna K. Slonim, Pablo Tamayo, Jill P. Mesirov, Todd R. Golub, Eric S. Lander 발표자 : 이인희.
Urine peptide biomarkers in Systemic Juvenile Idiopathic Arthritis (SJIA) Xuefeng B. Ling 1, Ken Lau 1, Jane Park 2,3, Claudia Macaubas 3, Jane C. Burns.
Systemic Onset Juvenile Rheumatoid Arthritis (SOJRA) Children present with spiking fevers, rash, enlarged liver / spleen, lymphadenopathy, systemic inflammation,
Classifier training FDR analysis Predictor discovery in training set 4 Training set SJIA (12 F, 12 Q) 1 DIGE raw gel images Matched samples SJIA (10 F,
Predictor discovery in training set 6 Training set SJIA (24 F, 14 Q) POLY (15 F, 10 Q) 1 DIGE raw gel images SJIA (13 F, 13 Q) POLY (5 F, 5 Q) Spot finding.
Predictor discovery in training set 6 Training set SJIA (24 F, 14 Q) POLY (15 F, 10 Q) 1 DIGE raw gel images SJIA (13 F, 13 Q) POLY (5 F, 5 Q) Spot finding.
CZ5225: Modeling and Simulation in Biology Lecture 7, Microarray Class Classification by Machine learning Methods Prof. Chen Yu Zong Tel:
Gene Discovery from Microarray Images 陳朝欽、 高成炎、張春梵 ARCNTU, NTU-Hospital Project#: 93-EC-17-A-19-S
Healthy ControlCase 2D gel images of Serum protein sample Set of gel images for analysis.
ControlDrug treated 2D gel images of bacterial protein sample Set of gel images for analysis.
DIAGNOSTIC PERFORMANCE OF A SEVEN-MARKER SERUM PROTEIN BIOSIGNATURE FOR THE DIAGNOSIS OF ACTIVE TB DISEASE IN AFRICAN PRIMARY HEALTH CARE CLINIC ATTENDEES.
Machine Learning with Spark MLlib
* Potential use of HP and AMBP in urine for the screening of prostate cancer Sanja Kiprijanovska1, Selim Komina2, Gordana Petrusevska2,
An Artificial Intelligence Approach to Precision Oncology
Volume 15, Pages (February 2017)
Volume 2, Issue 9, Pages (September 2015)
Circulating microRNAs as biomarkers in patients with allergic rhinitis and asthma  Ronaldo P. Panganiban, BS, Yanli Wang, BS, Judie Howrylak, MD, PhD,
Volume 85, Issue 4, Pages (April 2014)
Analytics in Higher Education: Methods Overview
Molecular Classification of Cancer
Knowledge l Action l Impact
Combining HMMs with SVMs
Volume 68, Issue 4, Pages (October 2015)
Host transcriptional profiling distinguishes patients with acute LRTI (LRTI+C+M) from those with noninfectious acute respiratory illness (no-LRTI). Host.
Analysis of differentially expressed proteins involved in hand, foot and mouth disease and normal sera  L. Deng, H.-L. Jia, C.-W. Liu, K.-H. Hu, G.-Q.
Volume 64, Issue 6, Pages (December 2013)
Proteomic Analysis Of The Potato Tuber Life Cycle
Circulating microRNAs as biomarkers in patients with allergic rhinitis and asthma  Ronaldo P. Panganiban, BS, Yanli Wang, BS, Judie Howrylak, MD, PhD,
Figure 1: Serum LDH levels elevated significantly in KD and febrile non-KD patients. LDH levels were respectively measured in KD, compared with FC and.
Volume 85, Issue 4, Pages (April 2014)
Plasma Biomarkers in Graft-versus-Host Disease: A New Era?
Softberry Mass Spectra (SMS) processing tools
Volume 4, Issue 3, Pages (August 2013)
Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage–derived cytokines  Allan R. Brasier, MD, Sundar Victor, MS,
Receiver operator characteristic (ROC) curve analysis of the plasma biomarker panels for differentiating ARDS (cases) from controls in patients with severe.
Analysis of differentially expressed proteins involved in hand, foot and mouth disease and normal sera  L. Deng, H.-L. Jia, C.-W. Liu, K.-H. Hu, G.-Q.
Basics of ML Rohan Suri.
Quality Assurance of RNA Expression Profiling in Clinical Laboratories
Differential gene expression in whole blood from SJIA patients and healthy controls. A. Data were normalized in Beadstudio using the "average" method and.
Volume 85, Issue 4, Pages (April 2014)
Talk outline Brief history of gene-expression profiling for cancer type classification Current commercially available tests - development and performance.
Figure 1. Identification of three tumour molecular subtypes in CIT and TCGA cohorts. We used CIT multi-omics data ( Figure 1. Identification of.
Predicting drug sensitivity from proteomic (RPPA) data clusters.
Untargeted LC/MS metabolite profiling of DFMO-treated HT-29 colorectal cancer cells. Untargeted LC/MS metabolite profiling of DFMO-treated HT-29 colorectal.
Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib by Chung H. Kok, David T.
Identification of putative TET1 targets in TNBC
Presentation transcript:

Classifier training Mann Whitney Predictor discovery in training set 4 Training set SJIA (12 F, 12 Q) POLY (13 F, 10 Q) 1 DIGE raw gel images SJIA (10 F, 10 Q) POLY (5 F, 5 Q) Spot finding spot alignment feature extraction 889 discrete spot features Classifier training Classify SJIA F vs Q POLY F vs Q DIGE analysis Prediction analysis (LDA) Predictor test in testing set 5 Testing set SJIA (10 F, 10 Q) POLY (10 F, 5 Q) 2 Cluster analysis 2d hierarchical clustering heatmap plotting Normalization manual review Manual review MSMS ID 96 spots 3 8 protein candidates Assay development 7 ELISA assays 7 Discriminate SJIA F KD FI SJIA PLASMA BIOMARKER DISCOVERY STUDY DESIGN Clustering Box-and-Whisker Analysis Discriminate SJIA F SJIA Q POLY F POLY Q ELISA assays ELISA assay FC (27 ) KD (10) Two class classification Classification analysis 9 ELISA assay Q->F (11) Q->Q (14) Test to anticipate SJIA F in Q LDA Fisher exact test P < randomization Blind testing Classify SJIA F vs Q POLY F vs Q Fisher exact test Training set SJIA F(12) KD (7), FC (15) Classify SJIA F vs Non SJIA F Testing set SJIA F(10) KD (3), FC (12) randomization Blind testing Classify SJIA F vs Non SJIA F Fisher exact test 8

Two dimensional DIGE analysis identified 96 protein spots differentially expressed between SJIA flare and quiescence A BC FQFQ SJIAPOLY FQ SJIA FQ POLY

DIGE analysis reveals a seven protein biomarker panel in plasma clearly differentiating SJIA flare from quiescence BCD FQFQ SJIAPOLY FQ SJIA FQ POLY A2M APOA1 SAP CRP HP MRP14 SAA MRP8 A2M APOA1 SAP CRP HP MRP14 SAA MRP8 FQFQ SJIAPOLY APOA1SAPCRPHPMRP14SAAMRP8 Relative expression A2M A

Training set n = Clinical diagnosis FQ n = LDA Classified as F Classified as Q Percent Agreement with clinical diagnosis 91.6% +- Overall P = 1.0 X Testing set n = Clinical diagnosis FQ n = Testing Classified as F Classified as Q Percent Agreement with clinical diagnosis 80%70% +- 75% Overall P = 7 X B CA Biomarker panel of 7 members 1.A2M 2.APO AI 3.CRP 4.HP 5.MRP8/MRP14 6.SAA 7.SAP SJIA D Training SJIA FSJIA QSJIA FSJIA Q Testing Predicted probabilities Patient samples E Sensitivity 1- Specificity CRP : AUC=0.58 SJIA F vs. Q panel : AUC=0.82 ESR : AUC=0.86 ELISA analysis validates the seven protein biomarker panel in plasma

Training set n = Clinical diagnosis FQ n = LDA Classified as F Classified as Q Percent Agreement with clinical diagnosis 76.9%50% % Overall P = 0.41 Testing set n = Clinical diagnosis FQ n = Testing Classified as F Classified as Q Percent Agreement with clinical diagnosis 30%100% % Overall P = 0.20 A B POLY C Training PFPQPFPQ Testing Predicted probabilities Patient samples D 1- Specificity CRP : AUC=0.64 POLY F vs. Q panel : AUC=0.64 Sensitivity ELISA analysis invalidates the seven protein biomarker panel in POLY plasma

Training set n = Clinical diagnosis QFQQ n = LDA Classified as QF Classified as QQ Percent Agreement with clinical diagnosis 54.5%85.7% +- 72% Overall P = 0.08 A SJIA B Predicted probabilities Patient samples C CRP : AUC=0.59 SJIA QF vs. QQ panel : AUC=0.78 ESR : AUC=0.60 Training QQQF Sensitivity 1- Specificity ELISA analysis shows the ineffectiveness of seven protein plasma biomarker panel in prognosis of impending SJIA flare

B C MRP14 FKDFC SJIA A2M APOA1 SAP CRP HP SAA MRP SJIA F KDFCData set n = Clinical diagnosis SJIA F NOT-SJIA F n = Unsupervised clustering Clustered as SJIA F Clustered as NOT-SJIA F Percent Agreement with clinical diagnosis 70%95.8% % Overall P = 1.6 X Protein quantity FKDFC SJIA APOA1SAPCRPHPMRP14SAAMRP8A2M A DIGE analysis shows that seven protein SJIA flare panel in plasma clearly differentiating SJIA flare from confounding Kawasaki and febrile illness

Training set n = Clinical diagnosis n = LDA Percent Agreement with clinical diagnosis 100% +- Overall P = 7.4X Testing set n = Clinical diagnosis n = Testing Percent Agreement with clinical diagnosis 90% 100% % Overall P = 4.9 X AB SJIA F C Training FC Testing Predicted probabilities Patient samples SJIA F KDFC NOT SJIA F SJIA F NOT SJIA F SJIA F KDFC KDSJIA FFCKDSJIA F Clustered as SJIA F Clustered as NOT SJIA F ELISA analysis validates the utility of the seven protein SJIA flare panel in plasma to discriminate SJIA flare from confounding Kawasaki and febrile illness

Training set n = Clinical diagnosis FQ n = LDA Classified as F Classified as Q Percent Agreement with clinical diagnosis 68.8%87% % Overall P = 6.0X Bootstrap set n = Clinical diagnosis FQ n = Testing Classified as F Classified as Q Percent Agreement with clinical diagnosis 85.3%82.1% % Overall P = 5.9 X B C SJIA D Training SFSQSFSQ Bootstrap confirmation Predicted probabilities Patient samples E 1- Specificity Bootstrap : AUC=0.90 SJIA F vs. Q Training : AUC=0.84 Sensitivity A Biomarker panel of 7 members 1.TIMP1 2.MMP9 3.IL18 4.RANTES Agilent protein array analysis reveals a four protein SJIA flare panel in plasma clearly differentiating SJIA flare from quiescence

Training set n = Clinical diagnosis FQ n = LDA Classified as F Classified as Q Percent Agreement with clinical diagnosis 100%85.7% % Overall P = 0.01 Bootstrap set n = Clinical diagnosis FQ n = Testing Classified as F Classified as Q Percent Agreement with clinical diagnosis 83.3%80% % Overall P = 0.03 A B POLY C Training PFPQPFPQ Predicted probabilities Patient samples D 1- Specificity Bootstrap: AUC=0.91 POLY F vs. Q Training: AUC=1 Sensitivity A Biomarker panel of 4 members 1.TIMP2 2.IGFBP-3 3.IGFBP-6 4.VCAM-1 Agilent protein array analysis reveals a four protein POLY flare panel in plasma clearly differentiating POLY flare from quiescence Bootstrap confirmation